Physician profile
Cha Lee
NPI 1285743971
$2,785.50
in general payments reported to CMS, 2019-2025
34 companies · $139 in 2025
The $139 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $567 · 2020: $399 · 2021: $570 · 2022: $589 · 2023: $254 · 2024: $268 · 2025: $139.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $660.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $469.22 | 2019-2023 | Farxiga |
| Abbvie INC. | $340.92 | 2019-2024 | |
| Lilly USA, LLC | $288.76 | 2019-2024 | Mounjaro, Zepbound |
| Pfizer INC. | $270.62 | 2019-2024 | |
| Acera Surgical, INC. | $139.01 | 2025 | Restrata Wound Matrix |
| Gilead Sciences, INC. | $111.80 | 2019-2022 | |
| Glaxosmithkline, LLC. | $108.68 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $99.24 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $97.94 | 2019-2023 | |
| Allergan, INC. | $75.19 | 2019-2020 | |
| Novo Nordisk INC | $72.75 | 2020-2024 | Ozempic, Rybelsus |
| Sanofi Pasteur INC. | $70.91 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $65.82 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Amgen INC. | $55.08 | 2021-2023 | Evenity, Prolia, Repatha |
| Exact Sciences Corporation | $53.85 | 2023-2024 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $42.43 | 2021-2023 | Krystexxa |
| Janssen Pharmaceuticals, INC | $41.09 | 2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $36.84 | 2019 | |
| Almatica Pharma LLC | $32.61 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $32.48 | 2019 | |
| Seqirus USA INC | $32.43 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $31.48 | 2022 | |
| Dexcom, INC. | $22.75 | 2021 | |
| Daiichi Sankyo INC. | $22.32 | 2021 | |
| Ironwood Pharmaceuticals, INC | $20.77 | 2021 | |
| Nestle Healthcare Nutrition INC. | $19.41 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.86 | 2023 | |
| Sunovion Pharmaceuticals INC. | $18.69 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.63 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.82 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $16.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $14.81 | 2024 | |
| Alnylam Pharmaceuticals INC. | $14.70 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cha Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.